Please assess the completion status of the following clinical trial:

Trial Title: Mechanistically-based Optimization of UV Radiation Therapy in Psoriasis

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* The presence of plaque-type psoriasis in areas of the trunk, buttocks, or extremities that are amenable to biopsy and evaluable disease in at least 2 cm target treatment sites separated by 1 cm~* Age 18-80, both genders, all ethnicities~* No contraindications to phototherapy or biopsy procedures~* No topical steroid, tar, phototherapy, Vitamin D, or retinoid therapy to target lesions for at least 1 week prior to the study~* No systemic psoriasis therapy for at least four weeks prior to the study~* Able to give informed consent under IRB approval procedures~Exclusion Criteria:~* Photosensitivity disorders~* Active untreated diseases or medication usage which may interfere with UVB, wound healing, or immune function~* Hypersensitivity to local anesthetic~* Inability to provide informed consent~* Pregnancy and /or lactating

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Imiquimod (Type: OTHER): Each study subject served as his/her own control. For this arm of the study, topical vehicle was applied to one plaque for 5 days. Imiquimod (5% topical cream) was applied to two psoriasis plaques for 5 days. Skin biopsies were taken from half of each of the 3 plaques at specific time points after completion of topical pre-treatment. The other half of the plaques were exposed to UVB light (via Excimer laser). Biopsies were subsequently taken at a specified time point.
- Clobetasol (Type: OTHER): Each study subject served as his/her own control. For this arm of the study, topical vehicle was applied to one plaque for 5 days. Clobetasol propionate 0.05% was applied to two psoriasis plaques for 5 days. Skin biopsies were taken from half of each of the 3 plaques at specific time points after completion of topical pre-treatment. The other half of the plaques were exposed to UVB light (via Excimer laser). Biopsies were subsequently taken at a specified time point.

Based on this trial design, predict the completion outcome and termination type (if applicable).